Price
Target price
€89.50
€89.50
-2.190%
-
-2.190%
€95.68
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Protagonist Therapeutics Inc Stock
A loss of -2.190% shows a downward development for Protagonist Therapeutics Inc.
The stock is one of the favorites of our community with 26 Buy predictions and 1 Sell predictions.
With a target price of 95 € there is a slightly positive potential of 6.15% for Protagonist Therapeutics Inc compared to the current price of 89.5 €.
So far the community has only identified positive things for Protagonist Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Protagonist Therapeutics Inc in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
Protagonist Therapeutics (PTGX) had its price target raised by Leerink Partners from $107.00 to $110.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its price target raised by JPMorgan Chase & Co. from $95.00 to $106.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its price target raised by Citigroup Inc. from $115.00 to $125.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
News
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
Hedge fund BVF reported a full exit from Protagonist Therapeutics (NASDAQ:PTGX) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million.
According to its
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
On Feb. 6, 2026, William D. Waddill, a director at Protagonist Therapeutics (NASDAQ:PTGX), exercised his stock options and immediately sold 20,000 shares, generating a transaction value of
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes
Arturo Molina, Chief Medical Officer of Protagonist Therapeutics (NASDAQ:PTGX), directly sold 9,514 shares in an open-market transaction on Jan. 20, 2026, for an approximate value of $784,700